|
AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss
RECRUITINGPhase 3Sponsored by Novo Nordisk A/S
Actively Recruiting
PhasePhase 3
SponsorNovo Nordisk A/S
Started2026-04-21
Est. completion2028-06-06
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations13 sites
View on ClinicalTrials.gov →
NCT07503210
Summary
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: * Male or female (sex at birth). * Age 18 years or above at the time of signing the informed consent. Exclusion Criteria: * Glycated haemoglobin (HbA1c) greater than or equal to ≥ 6.5% \[48 millimoles per mole (mmol/mol)\] as measured by the central laboratory at screening. * History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records. * Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP 1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment), or amylin analogues before screening.
Conditions2
ObesityWeight Loss
Interventions2
Locations13 sites
Pinnacle Research Group LLC
Anniston, Alabama, 36207
Diablo Clinical Research, Inc.
Endeavor Health
Midwest Inst For Clin Res
Find trials near these locations
Weight Loss trials in OrlandoWeight Loss trials in IndianapolisWeight Loss trials in PhiladelphiaWeight Loss trials in DallasAll trials in CaliforniaAll trials in FloridaAll trials in IllinoisAll trials in IndianaAll trials in North CarolinaAll trials in PennsylvaniaAll trials in TexasAll trials in VirginiaAll trials in Washington
Related trials
- Investigating How NNC0487-0111 Regulates Insulin of Adults With Type 2 Diabetes — Novo Nordisk A/S
- AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight — Novo Nordisk A/S
- AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea — Novo Nordisk A/S
- A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain — Novo Nordisk A/S
- AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain — Novo Nordisk A/S
- AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea — Novo Nordisk A/S
- AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight — Novo Nordisk A/S
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 3
SponsorNovo Nordisk A/S
Started2026-04-21
Est. completion2028-06-06
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations13 sites
View on ClinicalTrials.gov →
NCT07503210